DURHAM, N.C., Sept. 26, 2016 /PRNewswire/ -- Spyryx Biosciences, a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, announced today that John Taylor, President and CEO, will present at the Jefferies Cystic Fibrosis Summit on Thursday, September 29, 2016, at 12:00 p.m. ET in New York, NY.
Mr. Taylor will provide an update on the Company's corporate progress and clinical activities focused on SPX-101, a SPLUNC1-derived peptide shown pre-clinically to modulate a natural pathway that plays an important role in regulating airway surface liquid in the human lung, which is of particular interest in cystic fibrosis.
Event: Jefferies Cystic Fibrosis Summit
New York, NY
Presenter: John Taylor, President & CEO, Spyryx
Date: September 29, 2016
Time: 12:00 PM Eastern Standard Time
About Spyryx Biosciences
Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx's lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis that is currently completing a Phase 1 safety study. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function in cystic fibrosis patients independent of their genotype. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.
SOURCE Spyryx Biosciences